Froedtert Memorial Lutheran Hospital, INC.

Froedtert Memorial Lutheran Hospital, INC. was paid $157.85M by Medicaid between Jan 2018 and Dec 2024, across 986 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 11% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	787,533	$23.48M
2019	766,655	$23.13M
2020	638,708	$20.52M
2021	783,438	$23.04M
2022	785,693	$22.12M
2023	865,214	$24.54M
2024incomplete	751,307	$21.03M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	11%	244,360	194,888	$17.36M
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	5.2%	122,463	104,341	$8.23M
96361	Intravenous infusion, hydration; each additional hour	4.7%	54,372	37,991	$7.44M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	3.6%	95,415	79,738	$5.75M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	3.2%	75,516	64,637	$5.01M
80048	Basic metabolic panel (calcium, ionized)	3.0%	168,391	121,389	$4.81M
80053	Comprehensive metabolic panel	2.7%	114,062	79,426	$4.20M
J9271	Injection, pembrolizumab, 1 mg	2.2%	2,283	1,652	$3.45M
P9016	Red blood cells, leukocytes reduced, each unit	2.2%	4,928	3,915	$3.45M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	2.1%	39,534	25,428	$3.29M
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	1.8%	59,814	49,299	$2.88M
77386		1.3%	12,543	1,192	$2.12M

974 more codes

96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	1.3%	19,035	$2.05M
70450	Computed tomography, head or brain; without contrast material	1.3%	24,696	$2.04M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.2%	24,087	$1.88M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.2%	28,229	$1.83M
99213	Doctor's office visit, returning patient (routine)	1.1%	24,993	$1.78M
99282	Emergency department visit for the evaluation and management, low to moderate severity	1.1%	22,625	$1.67M
J0585	Injection, onabotulinumtoxina, 1 unit	1.0%	15,135	$1.61M
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1.0%	3,433	$1.61M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	59,839	$1.42M
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	16,786	$1.33M
Q3014	Telehealth originating site facility fee	<1%	32,407	$1.30M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	3,101	$1.25M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	209,167	$1.24M
96415		<1%	10,306	$1.21M
J2505	Injection, pegfilgrastim, 6 mg	<1%	1,543	$1.07M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	9,000	$986K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	26,388	$941K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	4,502	$895K
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	2,201	$852K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	16,688	$849K
96367		<1%	10,796	$842K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	12,041	$837K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	11,930	$833K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	13,597	$832K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	26,429	$828K
85610		<1%	56,934	$808K
77412		<1%	6,247	$805K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	7,824	$801K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	135,466	$774K
36512		<1%	1,811	$738K
99214	Doctor's office visit, returning patient (more involved)	<1%	9,442	$711K
52000		<1%	2,444	$705K
36430		<1%	6,520	$694K
G0378	Hospital observation service, per hour	<1%	26,680	$690K
J9299	Injection, nivolumab, 1 mg	<1%	930	$674K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	<1%	1,622	$660K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	3,645	$615K
71275	Computed tomographic angiography, chest, with contrast material	<1%	7,001	$610K
78815	Positron emission tomography (PET) for limited area imaging	<1%	2,549	$584K
99285	Emergency room visit (most serious)	<1%	8,994	$575K
99215	Doctor's office visit, returning patient (complex)	<1%	8,765	$566K
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	520	$518K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	2,738	$514K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	5,056	$497K
J0475	Injection, baclofen, 10 mg	<1%	2,257	$494K
64643		<1%	3,810	$461K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	11,645	$451K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	24,561	$439K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	19,376	$422K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	11,104	$409K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	4,290	$405K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	65,697	$403K
85027		<1%	81,460	$399K
80076		<1%	36,064	$398K
C9257	Injection, bevacizumab, 0.25 mg	<1%	2,497	$392K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	5,245	$391K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	21,660	$386K
72125	Computed tomography, cervical spine; without contrast material	<1%	10,815	$382K
84484		<1%	54,552	$382K
80081		<1%	3,596	$376K
87077		<1%	18,571	$367K
82962		<1%	14,108	$365K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	18,795	$362K
93308		<1%	2,969	$359K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	1,567	$347K
96910		<1%	6,125	$336K
64615		<1%	3,712	$328K
83735		<1%	78,295	$325K
83036	Hemoglobin; glycosylated (A1C)	<1%	35,760	$323K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	5,988	$320K
49083		<1%	2,063	$317K
77336		<1%	5,921	$310K
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	<1%	274	$310K
87086	Culture, bacterial; quantitative colony count, urine	<1%	31,204	$309K
83021		<1%	11,022	$306K
84443	Thyroid stimulating hormone (TSH)	<1%	27,351	$305K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	717	$303K
96417		<1%	5,808	$299K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	7,281	$297K
20610		<1%	5,137	$295K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	4,393	$294K
74183		<1%	3,040	$292K
76819	Fetal biophysical profile; without non-stress testing	<1%	9,924	$277K
83880		<1%	13,227	$273K
95874		<1%	7,214	$273K
81025		<1%	20,197	$268K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	3,919	$267K
80061	Lipid panel	<1%	18,218	$266K
76830	Ultrasound, transvaginal	<1%	6,164	$266K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	4,957	$255K
87536		<1%	4,210	$252K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	6,744	$251K
97162		<1%	9,311	$248K
J2357	Injection, omalizumab, 5 mg	<1%	2,357	$244K
95806		<1%	2,077	$244K
70496		<1%	2,563	$244K
76642		<1%	6,006	$238K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	10,550	$236K
64644		<1%	3,930	$236K
81001		<1%	64,716	$235K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	1,327	$233K
51705		<1%	3,488	$232K
J0485	Injection, belatacept, 1 mg	<1%	3,293	$232K
J9312	Injection, rituximab, 10 mg	<1%	303	$230K
84702		<1%	9,561	$229K
82728		<1%	19,454	$225K
83970		<1%	8,897	$220K
72131		<1%	6,070	$218K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	2,890	$209K
95811		<1%	1,025	$207K
67028	Intravitreal injection of a pharmacologic agent	<1%	4,191	$206K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	5,987	$205K
43235		<1%	1,032	$201K
95886		<1%	2,895	$200K
76801		<1%	6,776	$195K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	2,794	$193K
93971		<1%	6,025	$193K
70498		<1%	2,396	$191K
36561		<1%	433	$191K
72141		<1%	2,811	$190K
70486		<1%	4,664	$188K
71250		<1%	5,118	$183K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	12,185	$181K
87210		<1%	13,725	$181K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	7,118	$180K
96368		<1%	3,356	$179K
90686		<1%	10,357	$177K
64616		<1%	1,909	$175K
76770		<1%	3,106	$175K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	3,507	$170K
72128		<1%	4,725	$170K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	<1%	203	$169K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	5,714	$168K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	5,480	$164K
93017		<1%	4,023	$163K
72197		<1%	1,543	$163K
86480		<1%	3,357	$161K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	947	$160K
83690		<1%	28,918	$157K
J1930	Injection, lanreotide, 1 mg	<1%	209	$152K
70491		<1%	2,079	$151K
94660		<1%	2,535	$147K
82565		<1%	10,051	$145K
82805		<1%	6,571	$145K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	2,254	$143K
71046	Radiologic examination, chest; 2 views	<1%	45,418	$142K
84100		<1%	54,235	$142K
97116		<1%	9,508	$139K
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	274	$139K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	1,369	$137K
17250		<1%	1,708	$137K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	356	$136K
82607		<1%	10,515	$136K
64642		<1%	2,318	$135K
84439		<1%	14,080	$134K
J0178	Injection, aflibercept, 1 mg	<1%	1,117	$128K
76813		<1%	3,637	$127K
72156		<1%	1,137	$127K
86832		<1%	1,892	$126K
31575		<1%	2,478	$126K
77301		<1%	595	$126K
93296		<1%	4,001	$126K
77290		<1%	1,245	$124K
00731		<1%	3,190	$124K
93451		<1%	226	$124K
96416		<1%	950	$123K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	10,339	$123K
38222		<1%	702	$123K
90715		<1%	9,969	$122K
87070		<1%	7,178	$119K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	3,918	$118K
73221		<1%	1,830	$118K
84132		<1%	8,972	$117K
80197		<1%	11,406	$115K
97163		<1%	5,612	$114K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	83,347	$113K
80050	General health panel	<1%	6,358	$112K
77300		<1%	2,044	$111K
83615		<1%	29,544	$111K
10060		<1%	1,393	$111K
93356		<1%	1,126	$110K
82784		<1%	7,763	$108K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	1,927	$108K
94010		<1%	7,934	$108K
86803		<1%	9,493	$108K
C8930	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision	<1%	1,020	$107K
86850		<1%	16,857	$106K
93976		<1%	2,341	$106K
76536		<1%	2,446	$106K
97161		<1%	3,001	$105K
87088		<1%	17,054	$105K
62370		<1%	2,154	$105K
86900		<1%	20,510	$104K
83605		<1%	11,407	$102K
82105		<1%	5,747	$101K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,652	$101K
87081		<1%	6,268	$101K
93321		<1%	942	$100K
J1453	Injection, fosaprepitant, 1 mg	<1%	3,690	$99K
86833		<1%	1,833	$98K
97166		<1%	4,169	$98K
19083		<1%	360	$98K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	<1%	2,637	$98K
77080		<1%	1,656	$96K
64645		<1%	989	$96K
77334		<1%	2,290	$96K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	67,453	$96K
77066	Tomosynthesis, mammo	<1%	3,887	$95K
86140		<1%	15,562	$95K
87497		<1%	3,750	$93K
82570		<1%	12,219	$92K
87186		<1%	13,590	$91K
97165		<1%	2,985	$91K
77065	Tomosynthesis, mammo	<1%	4,378	$91K
36902		<1%	270	$90K
77063	Screening digital breast tomosynthesis, bilateral	<1%	4,486	$90K
93798		<1%	2,062	$90K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	1,253	$88K
86923		<1%	7,365	$86K
86592		<1%	10,731	$86K
86902		<1%	3,027	$86K
94060		<1%	3,694	$85K
76882		<1%	2,010	$84K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	1,593	$84K
72158		<1%	964	$82K
93970		<1%	1,787	$82K
93922		<1%	3,647	$82K
76512		<1%	2,062	$82K
97535	Self-care/home management training, each 15 minutes	<1%	7,332	$81K
12002		<1%	992	$81K
J0588	Injection, incobotulinumtoxin a, 1 unit	<1%	668	$81K
84550		<1%	29,346	$80K
31579		<1%	553	$80K
74174		<1%	1,109	$79K
12001		<1%	971	$79K
20611		<1%	693	$78K
83550		<1%	14,751	$77K
82950		<1%	3,915	$76K
82746		<1%	7,596	$76K
74160		<1%	1,140	$76K
82947		<1%	4,375	$75K
83540		<1%	17,220	$74K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	3,216	$72K
31231		<1%	1,203	$72K
72157		<1%	712	$70K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	12,487	$67K
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	1,386	$67K
91322		<1%	1,159	$67K
J0586	Injection, abobotulinumtoxina, 5 units	<1%	706	$66K
G0008	Administration of influenza virus vaccine	<1%	14,409	$65K
43762		<1%	956	$65K
84153		<1%	4,327	$64K
82533		<1%	3,801	$64K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	291	$64K
74230		<1%	1,076	$64K
J2323	Injection, natalizumab, 1 mg	<1%	83	$64K
J2350	Injection, ocrelizumab, 1 mg	<1%	13	$62K
82024		<1%	1,951	$62K
84403		<1%	3,272	$62K
86360		<1%	1,824	$61K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	810	$61K
Q0222	Injection, bebtelovimab, 175 mg	<1%	68	$59K
29581		<1%	722	$59K
87040		<1%	8,992	$58K
87522	Neg quan hep c or qual rna	<1%	1,599	$58K
92557		<1%	2,772	$58K
82670		<1%	2,161	$57K
J1756	Injection, iron sucrose, 1 mg	<1%	5,446	$57K
86160		<1%	3,222	$56K
86334		<1%	5,594	$55K
74018		<1%	7,263	$55K
80177		<1%	3,354	$55K
82043		<1%	4,990	$54K
86359		<1%	1,892	$54K
01922		<1%	703	$53K
85379		<1%	7,034	$53K
73700		<1%	1,205	$52K
87799		<1%	2,492	$51K
64612		<1%	672	$51K
J9310	Injection, rituximab, 100 mg	<1%	70	$51K
82378		<1%	4,227	$51K
77001		<1%	2,308	$50K
77062		<1%	2,927	$50K
77061		<1%	2,995	$49K
82330		<1%	3,546	$49K
85730		<1%	13,538	$49K
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	286	$49K
97167		<1%	3,117	$48K
82550		<1%	6,910	$48K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	<1%	1,056	$48K
52287		<1%	262	$46K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	2,725	$46K
92134		<1%	13,849	$46K
82375		<1%	2,655	$45K
47562		<1%	28	$44K
J0897	Injection, denosumab, 1 mg	<1%	433	$44K
82077		<1%	4,376	$44K
92002		<1%	729	$44K
73030		<1%	11,185	$43K
73560		<1%	13,784	$43K
11900		<1%	697	$43K
77002		<1%	959	$43K
86706		<1%	6,353	$41K
80164		<1%	2,126	$41K
83516		<1%	3,952	$41K
87340		<1%	6,938	$41K
93325		<1%	1,517	$41K
51702		<1%	3,014	$40K
12011		<1%	580	$40K
80069		<1%	1,524	$40K
77295		<1%	202	$40K
80143		<1%	3,094	$40K
86039		<1%	4,085	$39K
97597		<1%	796	$39K
87450		<1%	3,801	$38K
92083		<1%	7,234	$38K
92611		<1%	942	$38K
70543		<1%	338	$37K
73630		<1%	10,880	$36K
84146		<1%	2,277	$36K
J1610	Injection, glucagon hydrochloride, per 1 mg	<1%	1,185	$35K
80175		<1%	1,687	$35K
87493		<1%	1,327	$35K
88307		<1%	5,267	$35K
82150		<1%	4,037	$35K
87632		<1%	261	$34K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	99	$34K
11104		<1%	303	$34K
88264		<1%	537	$34K
83001		<1%	2,217	$34K
J0791	Injection, crizanlizumab-tmca, 5 mg	<1%	112	$33K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	141	$33K
87641		<1%	836	$33K
36821		<1%	57	$33K
J9035	Injection, bevacizumab, 10 mg	<1%	48	$33K
G0257	Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility	<1%	1,489	$33K
86301		<1%	2,952	$33K
72100		<1%	4,905	$33K
84703		<1%	2,712	$33K
83883		<1%	3,421	$33K
58661		<1%	35	$32K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	<1%	57	$32K
81003		<1%	6,986	$32K
86304		<1%	2,313	$32K
70544		<1%	294	$32K
80179		<1%	2,948	$32K
58300		<1%	646	$32K
76942		<1%	3,251	$31K
86235		<1%	408	$31K
41899	Unlisted procedure, dentoalveolar structures	<1%	102	$31K
84156		<1%	12,270	$31K
00811		<1%	1,265	$30K
83010		<1%	3,174	$30K
92235		<1%	563	$30K
73610		<1%	11,540	$30K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	1,066	$30K
76937		<1%	3,331	$30K
59025	Fetal non-stress test	<1%	284	$29K
86704		<1%	3,149	$29K
11100		<1%	250	$29K
86901		<1%	15,700	$29K
84165		<1%	5,837	$29K
85097		<1%	951	$29K
93880		<1%	1,206	$29K
88275		<1%	772	$28K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	524	$28K
82040		<1%	2,191	$28K
73502		<1%	7,394	$28K
58100		<1%	265	$28K
91010		<1%	199	$27K
51728		<1%	250	$27K
86225		<1%	2,838	$27K
72040		<1%	1,807	$27K
84425		<1%	1,869	$26K
82248		<1%	5,542	$26K
J2997	Injection, alteplase recombinant, 1 mg	<1%	1,548	$26K
00813		<1%	796	$26K
93225		<1%	1,322	$26K
77470		<1%	252	$26K
84630		<1%	3,594	$26K
90935	Hemodialysis procedure with single evaluation by a physician	<1%	113	$25K
J0875	Injection, dalbavancin, 5 mg	<1%	36	$25K
81002		<1%	1,146	$25K
84145		<1%	1,813	$25K
77338		<1%	518	$25K
43760		<1%	207	$24K
85018		<1%	6,419	$24K
93320		<1%	228	$24K
84481		<1%	2,194	$24K
76519		<1%	601	$23K
76870		<1%	658	$23K
85049		<1%	1,647	$23K
36592		<1%	13,178	$23K
36591		<1%	18,118	$23K
64400		<1%	174	$23K
90670		<1%	988	$23K
P9047	Infusion, albumin (human), 25%, 50 ml	<1%	204	$22K
17110		<1%	376	$22K
11102		<1%	227	$21K
94726		<1%	3,463	$21K
86708		<1%	2,195	$21K
71045	Radiologic examination, chest; single view	<1%	29,405	$21K
94770		<1%	409	$21K
88112		<1%	2,297	$21K
G0422	Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session	<1%	1,028	$21K
92133		<1%	8,291	$20K
J3471	Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)	<1%	1,528	$20K
76000		<1%	2,308	$20K
87075		<1%	3,216	$20K
96375	Therapeutic injection; each additional sequential IV push	<1%	55,529	$20K
73130		<1%	8,261	$20K
83521		<1%	1,591	$20K
84466		<1%	2,267	$20K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	1,276	$20K
96900		<1%	1,165	$20K
86705		<1%	2,406	$20K
36415	Collection of venous blood by venipuncture	<1%	95,386	$19K
00400		<1%	326	$19K
85045		<1%	7,886	$19K
88271		<1%	732	$19K
82140		<1%	882	$19K
72146		<1%	282	$18K
78431		<1%	61	$18K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	33,754	$18K
88237		<1%	572	$18K
76820		<1%	1,562	$18K
85652		<1%	10,505	$18K
90480		<1%	1,189	$18K
84450		<1%	3,752	$18K
64646		<1%	391	$18K
87205		<1%	6,450	$17K
85014		<1%	3,479	$17K
82948		<1%	550	$17K
87529		<1%	288	$17K
84460		<1%	3,564	$17K
97542		<1%	1,646	$17K
83002		<1%	1,259	$17K
87102		<1%	2,157	$16K
92523		<1%	479	$16K
96523		<1%	541	$16K
87430		<1%	621	$16K
92020		<1%	1,036	$16K
96402		<1%	2,269	$15K
75561		<1%	157	$15K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,175	$15K
84305		<1%	1,085	$15K
95885		<1%	236	$15K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	<1%	14	$15K
87640		<1%	299	$14K
51741		<1%	354	$14K
93926		<1%	873	$14K
G0009	Administration of pneumococcal vaccine	<1%	3,875	$14K
87015		<1%	861	$14K
J9070	Cyclophosphamide, 100 mg	<1%	560	$14K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	39	$14K
94762		<1%	445	$14K
83921		<1%	887	$13K
72050		<1%	1,041	$13K
86316		<1%	1,043	$13K
88184		<1%	2,388	$13K
86922		<1%	2,028	$13K
90732		<1%	1,538	$13K
87206		<1%	2,735	$13K
87808		<1%	954	$12K
73110		<1%	5,230	$12K
86361		<1%	580	$12K
73562		<1%	3,414	$12K
94618		<1%	1,706	$12K
73552		<1%	5,384	$12K
20605		<1%	146	$12K
74019		<1%	1,660	$12K
90662		<1%	2,946	$11K
92610		<1%	592	$11K
36000		<1%	10,308	$11K
86644		<1%	1,072	$11K
51798		<1%	5,651	$11K
P9045	Infusion, albumin (human), 5%, 250 ml	<1%	237	$11K
20680		<1%	16	$11K
36832		<1%	14	$11K
83520		<1%	750	$11K
94729		<1%	4,699	$11K
10005		<1%	59	$11K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	74	$11K
00790		<1%	113	$11K
93270		<1%	575	$11K
95816		<1%	83	$10K
00840		<1%	148	$10K
88280		<1%	706	$10K
92250		<1%	5,175	$10K
73590		<1%	6,349	$10K
96401		<1%	1,515	$10K
90651		<1%	239	$10K
88185		<1%	2,233	$10K
78306		<1%	129	$10K
92567		<1%	1,042	$10K
90677		<1%	1,055	$9K
80165		<1%	899	$9K
86800		<1%	838	$9K
0124A		<1%	762	$9K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	50	$9K
72072		<1%	1,508	$9K
85651		<1%	3,776	$9K
0399T		<1%	303	$9K
67228		<1%	47	$9K
73080		<1%	3,660	$8K
89051		<1%	1,323	$8K
45300		<1%	43	$8K
0003A		<1%	424	$8K
86780		<1%	918	$8K
75574		<1%	78	$8K
76498		<1%	181	$8K
82010		<1%	1,191	$8K
85007		<1%	5,216	$8K
73564		<1%	1,841	$8K
90791	Psychiatric diagnostic evaluation	<1%	216	$8K
01844		<1%	90	$8K
82103		<1%	664	$8K
86769		<1%	270	$8K
80235		<1%	407	$8K
58301		<1%	147	$7K
43249		<1%	31	$7K
87517		<1%	269	$7K
82088		<1%	247	$7K
90656		<1%	963	$7K
96409		<1%	1,700	$7K
82310		<1%	940	$7K
80051		<1%	274	$7K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	16,455	$7K
20553		<1%	132	$7K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	226	$6K
87521	Neg quan hep c or qual rna	<1%	273	$6K
51797		<1%	612	$6K
87902		<1%	26	$6K
95911		<1%	143	$6K
74178		<1%	95	$6K
01480		<1%	104	$6K
29405		<1%	77	$6K
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	2,055	$6K
73521		<1%	779	$6K
82610		<1%	656	$6K
82747		<1%	532	$6K
0001A		<1%	225	$6K
J3489	Injection, zoledronic acid, 1 mg	<1%	1,212	$6K
86431		<1%	1,521	$6K
C1776	Joint device (implantable)	<1%	197	$6K
0002A		<1%	220	$6K
82977		<1%	1,005	$6K
93750		<1%	339	$6K
93242		<1%	294	$6K
94799		<1%	5,885	$6K
88342		<1%	3,873	$6K
J9041	Injection, bortezomib, 0.1 mg	<1%	50	$6K
88360		<1%	524	$6K
87106		<1%	827	$5K
86355		<1%	206	$5K
92504		<1%	667	$5K
87045		<1%	418	$5K
P9037	Platelets, pheresis, leukocytes reduced, irradiated, each unit	<1%	27	$5K
82785		<1%	292	$5K
86665		<1%	375	$5K
73090		<1%	2,964	$5K
71271		<1%	111	$5K
93975		<1%	110	$5K
95819		<1%	39	$5K
88341		<1%	1,172	$5K
96376		<1%	24,896	$5K
86787		<1%	839	$5K
36589		<1%	30	$5K
83050		<1%	2,213	$5K
86255		<1%	618	$5K
70546		<1%	52	$5K
90739		<1%	566	$5K
94667		<1%	320	$4K
00142		<1%	112	$4K
11721		<1%	274	$4K
72170		<1%	2,339	$4K
86880		<1%	1,209	$4K
93990		<1%	751	$4K
92136		<1%	943	$4K
89050		<1%	769	$4K
72190		<1%	1,762	$4K
88172		<1%	708	$4K
87116		<1%	676	$4K
82951		<1%	85	$4K
36558		<1%	17	$4K
74170		<1%	87	$4K
G0423	Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session	<1%	540	$4K
86762		<1%	321	$4K
L2112	Ankle foot orthosis, fracture orthosis, tibial fracture orthosis, soft, prefabricated, includes fitting and adjustment	<1%	329	$4K
86147		<1%	260	$4K
86870		<1%	247	$4K
95970		<1%	146	$4K
64999		<1%	43	$4K
95909		<1%	57	$4K
85520		<1%	76	$4K
84432		<1%	291	$4K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	55,531	$4K
36593		<1%	381	$4K
G0010	Administration of hepatitis b vaccine	<1%	1,020	$4K
80158		<1%	114	$4K
95912		<1%	112	$4K
73140		<1%	1,330	$3K
P9073	Platelets, pheresis, pathogen-reduced, each unit	<1%	30	$3K
00140		<1%	69	$3K
82104		<1%	360	$3K
80185		<1%	258	$3K
L2114	Ankle foot orthosis, fracture orthosis, tibial fracture orthosis, semi-rigid, prefabricated, includes fitting and adjustment	<1%	442	$3K
90740		<1%	75	$3K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	<1%	48	$3K
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	<1%	15	$3K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	55	$3K
80201		<1%	263	$3K
86357		<1%	123	$3K
82542		<1%	161	$3K
11982		<1%	17	$3K
73060		<1%	2,731	$3K
83519		<1%	145	$3K
91120		<1%	58	$3K
86200		<1%	369	$3K
19081		<1%	15	$3K
78816		<1%	12	$3K
87563		<1%	132	$3K
84244		<1%	186	$3K
97802		<1%	63	$3K
84134		<1%	327	$3K
Q0243	Injection, casirivimab and imdevimab, 2400 mg	<1%	93	$3K
87181		<1%	135	$3K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	12	$3K
87631		<1%	60	$3K
72110		<1%	256	$3K
J7325	Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	<1%	79	$3K
82627		<1%	207	$3K
95910		<1%	43	$3K
94664		<1%	249	$3K
78582		<1%	17	$3K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,258	$3K
29075		<1%	75	$3K
84207		<1%	159	$3K
J1726	Injection, hydroxyprogesterone caproate, (makena), 10 mg	<1%	125	$3K
00145		<1%	40	$3K
86335		<1%	203	$3K
80183		<1%	207	$3K
52310		<1%	12	$3K
81511		<1%	16	$3K
86381		<1%	249	$3K
92060		<1%	616	$3K
85347		<1%	223	$2K
36901		<1%	19	$2K
A9585	Injection, gadobutrol, 0.1 ml	<1%	17,203	$2K
76514		<1%	402	$2K
L3908	Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf	<1%	1,040	$2K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	3,795	$2K
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	<1%	14	$2K
72193		<1%	33	$2K
88304		<1%	2,414	$2K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	101	$2K
92526		<1%	180	$2K
36556		<1%	18	$2K
0054A		<1%	201	$2K
90750		<1%	307	$2K
86709		<1%	218	$2K
36590		<1%	13	$2K
Q9956	Injection, octafluoropropane microspheres, per ml	<1%	6,461	$2K
62368		<1%	17	$2K
91122		<1%	58	$2K
85384		<1%	334	$2K
84166		<1%	223	$2K
J2785	Injection, regadenoson, 0.1 mg	<1%	3,528	$2K
84080		<1%	314	$2K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	449	$2K
87046		<1%	419	$2K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	16	$2K
86308		<1%	197	$2K
86015		<1%	261	$2K
29515		<1%	69	$2K
36416		<1%	18,072	$2K
81206		<1%	19	$2K
92604		<1%	129	$2K
69210		<1%	222	$2K
95913		<1%	133	$2K
C1769	Guide wire	<1%	6,696	$2K
93986		<1%	230	$2K
82800		<1%	219	$2K
29125		<1%	187	$2K
84300		<1%	441	$2K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	46,020	$2K
87147		<1%	350	$2K
87486		<1%	77	$2K
C8924	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study	<1%	18	$2K
84446		<1%	197	$2K
80074		<1%	46	$2K
77049		<1%	12	$1K
86003		<1%	30	$1K
97035		<1%	122	$1K
81403		<1%	32	$1K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	29,855	$1K
86256		<1%	93	$1K
99195		<1%	114	$1K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	2,779	$1K
97760		<1%	120	$1K
87581		<1%	77	$1K
73000		<1%	394	$1K
C9053	Injection, crizanlizumab-tmca, 1 mg	<1%	19	$1K
86593		<1%	387	$1K
97803		<1%	21	$1K
12013		<1%	17	$1K
90620		<1%	48	$1K
84590		<1%	173	$1K
85613		<1%	135	$1K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	2,461	$1K
84270		<1%	70	$1K
88313		<1%	3,644	$1K
93246		<1%	35	$1K
20550		<1%	14	$1K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	4,368	$1K
G0444	Annual depression screening, 5 to 15 minutes	<1%	30	$1K
85660		<1%	240	$1K
99496		<1%	35	$1K
90678		<1%	151	$1K
36600		<1%	381	$1K
J1170	Injection, hydromorphone, up to 4 mg	<1%	26,050	$1K
0004A		<1%	106	$999.10
90746		<1%	82	$977.91
70487		<1%	14	$968.17
92591		<1%	66	$959.89
84075		<1%	211	$930.10
80156		<1%	27	$929.28
80186		<1%	119	$917.97
80169		<1%	89	$917.94
82390		<1%	114	$915.66
82553		<1%	189	$912.19
J9171	Injection, docetaxel, 1 mg	<1%	76	$904.54
87184		<1%	174	$879.32
90472	Immunization administration, each additional vaccine (list separately)	<1%	191	$855.04
96411		<1%	2,300	$821.83
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	21,550	$803.85
93299		<1%	16	$793.09
J9073	Injection, cyclophosphamide (dr. reddy's), 5 mg	<1%	25	$768.06
84157		<1%	156	$765.07
86376		<1%	64	$757.28
86146		<1%	62	$754.78
80203		<1%	42	$740.54
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	57,680	$739.50
77091		<1%	111	$724.93
92025		<1%	284	$722.80
72082		<1%	12	$684.71
92285		<1%	77	$657.03
80195		<1%	50	$652.05
87427		<1%	68	$645.02
83835		<1%	35	$644.42
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	5,000	$641.66
17000		<1%	30	$639.88
87899		<1%	51	$638.04
73523		<1%	248	$612.59
0031A		<1%	24	$606.33
88173		<1%	1,009	$582.10
88312		<1%	2,846	$531.19
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	5,076	$530.65
85732		<1%	92	$529.08
84295		<1%	54	$506.53
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	17,222	$498.45
82945		<1%	60	$498.01
93280		<1%	185	$488.71
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	38,552	$483.66
J7120	Ringers lactate infusion, up to 1000 cc	<1%	4,728	$478.94
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	404	$473.05
C9113	Injection, pantoprazole sodium, per vial	<1%	3,033	$465.97
J9395	Injection, fulvestrant, 25 mg	<1%	35	$456.45
95992		<1%	23	$435.53
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	28,279	$433.64
92593		<1%	28	$430.57
74246		<1%	14	$428.64
J1644	Injection, heparin sodium, per 1000 units	<1%	14,861	$426.56
86618		<1%	17	$422.61
G0296	Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)	<1%	93	$408.26
71100		<1%	199	$395.03
0052A		<1%	12	$381.60
82164		<1%	45	$375.81
84480		<1%	36	$370.35
94150		<1%	1,253	$360.58
87076		<1%	40	$352.72
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	7,596	$351.23
94761		<1%	3,139	$348.61
C1750	Catheter, hemodialysis/peritoneal, long-term	<1%	63	$338.34
91200		<1%	124	$327.97
70250		<1%	70	$322.17
98960		<1%	79	$319.92
J0780	Injection, prochlorperazine, up to 10 mg	<1%	6,143	$313.62
J2704	Injection, propofol, 10 mg	<1%	19,272	$264.16
Q0239	Injection, bamlanivimab-xxxx, 700 mg	<1%	15	$261.86
97763		<1%	19	$253.35
0352U		<1%	333	$252.10
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	<1%	32	$248.05
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	11,325	$245.77
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	2,751	$245.58
87209		<1%	14	$239.96
82436		<1%	80	$239.73
82247		<1%	98	$238.25
84478		<1%	61	$234.14
J2790	Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)	<1%	13	$226.80
J3475	Injection, magnesium sulfate, per 500 mg	<1%	9,316	$224.43
86905		<1%	40	$218.04
82435		<1%	68	$216.84
93282		<1%	49	$215.92
P9612	Catheterization for collection of specimen, single patient, all places of service	<1%	1,123	$210.05
84133		<1%	80	$207.52
83993		<1%	15	$203.81
J2060	Injection, lorazepam, 2 mg	<1%	5,762	$195.27
85598		<1%	16	$189.52
85597		<1%	17	$188.59
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	4,445	$172.39
46600		<1%	218	$168.74
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	2,845	$167.36
84155		<1%	88	$164.12
J0173	Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg	<1%	835	$160.98
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	173	$159.71
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	1,113	$158.85
C1766	Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away	<1%	299	$157.95
J0690	Injection, cefazolin sodium, 500 mg	<1%	13,786	$156.53
90734		<1%	13	$154.16
88311		<1%	1,186	$150.41
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	9,608	$140.37
90632		<1%	13	$135.59
82525		<1%	18	$130.14
96377		<1%	1,055	$126.30
87177		<1%	14	$124.71
85525		<1%	17	$124.13
Q9954	Oral magnetic resonance contrast agent, per 100 ml	<1%	567	$117.12
J3480	Injection, potassium chloride, per 2 meq	<1%	2,501	$109.88
72070		<1%	15	$107.47
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	<1%	2,214	$100.73
82009		<1%	17	$100.30
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	49	$97.61
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	4,460	$90.43
86906		<1%	37	$89.13
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	3,520	$87.30
71101		<1%	62	$86.55
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	2,905	$83.71
L3933	Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment	<1%	83	$82.81
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens	<1%	15	$77.47
J1939	Injection, bumetanide, 0.5 mg	<1%	129	$77.07
89060		<1%	14	$72.63
J0640	Injection, leucovorin calcium, per 50 mg	<1%	1,666	$70.09
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	613	$69.62
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	100	$65.80
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	3,080	$65.12
L0172	Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf	<1%	59	$54.03
73070		<1%	76	$53.80
82340		<1%	12	$51.60
85048		<1%	47	$49.15
84540		<1%	15	$46.29
84520		<1%	16	$39.01
J1940	Injection, furosemide, up to 20 mg	<1%	3,005	$38.12
82952		<1%	12	$36.54
V2632	Posterior chamber intraocular lens	<1%	1,606	$35.07
C1729	Catheter, drainage	<1%	1,260	$34.96
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	395	$30.26
L3906	Wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment	<1%	15	$28.27
J2270	Injection, morphine sulfate, up to 10 mg	<1%	5,355	$27.62
J9190	Injection, fluorouracil, 500 mg	<1%	2,192	$27.54
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	<1%	46	$24.81
77417		<1%	623	$24.16
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	3,757	$22.57
J0610	Injection, calcium gluconate (fresenius kabi), per 10 ml	<1%	634	$22.10
J0461	Injection, atropine sulfate, 0.01 mg	<1%	1,095	$19.81
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	13	$18.18
J9045	Injection, carboplatin, 50 mg	<1%	2,231	$17.96
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	9,062	$17.89
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	169	$17.50
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	1,091	$16.55
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	2,816	$15.86
J8540	Dexamethasone, oral, 0.25 mg	<1%	6,725	$15.67
J0612	Injection, calcium gluconate, not otherwise specified, 10 mg	<1%	360	$15.33
J1805	Injection, esmolol hydrochloride, 10 mg	<1%	409	$14.90
J3370	Injection, vancomycin hcl, 500 mg	<1%	2,247	$14.45
72020		<1%	26	$14.42
77387		<1%	433	$12.08
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	822	$10.64
C1726	Catheter, balloon dilatation, non-vascular	<1%	326	$9.88
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	12,150	$9.05
J9267	Injection, paclitaxel, 1 mg	<1%	1,440	$8.37
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	341	$8.28
91312		<1%	375	$7.82
J1790	Injection, droperidol, up to 5 mg	<1%	3,071	$6.94
J1630	Injection, haloperidol, up to 5 mg	<1%	2,031	$6.29
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	894	$5.77
C1760	Closure device, vascular (implantable/insertable)	<1%	599	$3.70
J3411	Injection, thiamine hcl, 100 mg	<1%	1,465	$3.54
J3473	Injection, hyaluronidase, recombinant, 1 usp unit	<1%	150	$3.07
A4648	Tissue marker, implantable, any type, each	<1%	59	$3.03
86790		<1%	14	$2.87
J1953	Injection, levetiracetam, 10 mg	<1%	839	$1.51
J0697	Injection, sterile cefuroxime sodium, per 750 mg	<1%	1,003	$1.12
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	487	$0.99
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	332	$0.64
J1836	Injection, metronidazole, 10 mg	<1%	496	$0.30
91305		<1%	204	$0.14
J0280	Injection, aminophyllin, up to 250 mg	<1%	157	$0.07
91303		<1%	23	$0.02
88365		0%	16	$0.00
C1758	Catheter, ureteral	0%	663	$0.00
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	0%	2,558	$0.00
A9575	Injection, gadoterate meglumine, 0.1 ml	0%	152	$0.00
C1788	Port, indwelling (implantable)	0%	442	$0.00
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	0%	108	$0.00
73100		0%	31	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	422	$0.00
73551		0%	13	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	458	$0.00
J9999	Not otherwise classified, antineoplastic drugs	0%	329	$0.00
91300		0%	761	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	308	$0.00
88346		0%	35	$0.00
88302		0%	86	$0.00
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	0%	265	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	231	$0.00
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	0%	502	$0.00
C2625	Stent, non-coronary, temporary, with delivery system	0%	261	$0.00
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	110	$0.00
73010		0%	25	$0.00
92081		0%	17	$0.00
G8990	Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals	0%	18	$0.00
G8989	Self care functional limitation, discharge status, at discharge from therapy or to end reporting	0%	225	$0.00
J0692	Injection, cefepime hydrochloride, 500 mg	0%	146	$0.00
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	0%	111	$0.00
77012		0%	64	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	109	$0.00
0441U		0%	50	$0.00
J1580	Injection, garamycin, gentamicin, up to 80 mg	0%	75	$0.00
J9000	Injection, doxorubicin hydrochloride, 10 mg	0%	52	$0.00
C1752	Catheter, hemodialysis/peritoneal, short-term	0%	16	$0.00
L0140	Cervical, semi-rigid, adjustable (plastic collar)	0%	12	$0.00
0100U		0%	24	$0.00
J1071	Injection, testosterone cypionate, 1 mg	0%	17	$0.00
J2310	Injection, naloxone hydrochloride, per 1 mg	0%	15	$0.00
J9060	Injection, cisplatin, powder or solution, 10 mg	0%	24	$0.00
A9270	Non-covered item or service	0%	492	$0.00
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	0%	359	$0.00
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	0%	109	$0.00
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	472	$0.00
J0706	Injection, caffeine citrate, 5 mg	0%	14	$0.00
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	0%	116	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	465	$0.00
C1830	Powered bone marrow biopsy needle	0%	53	$0.00
J3360	Injection, diazepam, up to 5 mg	0%	134	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	494	$0.00
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	0%	74	$0.00
J1920	Injection, labetalol hydrochloride, 5 mg	0%	531	$0.00
J2795	Injection, ropivacaine hydrochloride, 1 mg	0%	823	$0.00
G9172	Voice functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	14	$0.00
C9290	Injection, bupivacaine liposome, 1 mg	0%	145	$0.00
J2470	Injection, pantoprazole sodium, 40 mg	0%	110	$0.00
L3808	Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment	0%	66	$0.00
76377		0%	59	$0.00
C1781	Mesh (implantable)	0%	49	$0.00
G8983	Changing & maintaining body position functional limitation, discharge status, at discharge from therapy or to end reporting	0%	31	$0.00
J1030	Injection, methylprednisolone acetate, 40 mg	0%	14	$0.00
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	144	$0.00
G8991	Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	19	$0.00
J8501	Aprepitant, oral, 5 mg	0%	30	$0.00
G8986	Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting	0%	13	$0.00
A9540	Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries	0%	47	$0.00
G8998	Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting	0%	42	$0.00
88350		0%	35	$0.00
J7507	Tacrolimus, immediate release, oral, 1 mg	0%	46	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	29	$0.00
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	0%	14	$0.00
J0500	Injection, dicyclomine hcl, up to 20 mg	0%	32	$0.00
J1040	Injection, methylprednisolone acetate, 80 mg	0%	35	$0.00
73600		0%	19	$0.00
L4350	Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf	0%	43	$0.00
88300		0%	12	$0.00
J2471	Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg	0%	26	$0.00
C1893	Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away	0%	21	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialREEDER, AUSTIN (PRESIDENT)

Same official

Other billing entities under REEDER, AUSTIN

Full network →

Provider	Location	Paid
Hospital Service Dist. No. 1 of the Parish of ST. Charles, State of LA	Luling, LA	$13.85M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.